Prevail Therapeutics
Clinical trials sponsored by Prevail Therapeutics, explained in plain language.
A gene therapy company developing treatments for neurodegenerative diseases.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New gene therapy targets Parkinson's in patients with specific gene flaw
Disease control OngoingThis study tests a new gene therapy called LY3884961 in 32 people with moderate to severe Parkinson's disease who have a specific genetic change (GBA1 mutation). The treatment is given as a single injection into the fluid around the brain and spinal cord. The main goal is to chec…
Phase: PHASE1, PHASE2 • Sponsor: Prevail Therapeutics • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Gene therapy trial targets inherited dementia
Disease control OngoingThis study tests a single-dose gene therapy called LY3884963 in 35 people with frontotemporal dementia caused by GRN gene mutations. The therapy aims to raise levels of a missing protein (progranulin) in the brain. Participants receive the treatment via injection into the fluid a…
Phase: PHASE1, PHASE2 • Sponsor: Prevail Therapeutics • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Gene therapy injection aims to halt fatal brain disease in babies
Disease control OngoingThis early-phase trial is testing a single-dose gene therapy called LY3884961 in 7 infants with Type 2 Gaucher disease, a severe and rapidly fatal genetic disorder. The therapy is injected into the fluid around the brain and spinal cord to deliver a working copy of the faulty gen…
Phase: PHASE1, PHASE2 • Sponsor: Prevail Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC